Showing results (381-390 of 1,343) with videos related to
Sort By:
Pageof 135
Revue Medicale De Liege|May 2, 2003
[Optimizing the management of type 2 diabetics: results of the "DREAM" study in general practice]A J Scheen, G Bruwier, H SchmittRevue Medicale De Liege|February 29, 2008
[Medication of the month. Rimonabant (Acomplia): first CB1 receptor antagonist of the endocannabinoid system]A J Scheen, L F Van GaalRevue Medicale De Liege|June 20, 2008
[Medication of the month... Exenatide (Byetta) incretinomimetic in the treatment of type 2 diabetes after failure and as add-on therapy to oral agents]A J Scheen, L F Van GaalRevue Medicale De Liege|December 31, 2008
[Benefit-risk ratio of coronary drug-eluting stents: 2nd part: evaluation in the diabetic population]A Nyssen, V Legrand, A J ScheenRevue Medicale De Liege|July 23, 2005
[Initiave to promote quality of care and epidemiology of diabetes mellitus]F Nobels, N Debacker, A J Scheen, et al.Revue Medicale De Liege|August 17, 2006
[Advices for a better drug prescription]A J Scheen, A Parada, D GietRevue Medicale De Liege|September 28, 2011
[Glycemic control before and after sitagliptin in general medical practice: analysis of determinant factors in the Belgian observational study "SUGAR"]A J Scheen, L F Van GaalRevue Medicale De Liege|November 20, 2010
[Clinical study of the month. Accord-lipid and accord-eye: towards a new positioning of fenofibrate in the management of type 2 diabetes]A J Scheen, L F Van GaalRevue Medicale De Liege|July 29, 2014
[Diabetes mellitus in the elderly: from the epidemiological challenge to a personalized approach]A J Scheen, N Paquot, B BauduceauRevue Medicale De Liege|December 5, 2013
[Sitagliptin in the treatment of type 2 diabetes: insights five years after commercialisation]A J Scheen, L F Van GaalPageof 135